ImmunisLogoWImmunisLogocropped-immunislogo.pngcropped-immunislogo.png
  • Home
  • About Us
    • Mission
    • Technology
    • Leadership
  • Overview
    • Pipeline
    • STEM-MYO Program
      • Phase 1/2a Clinical Trial
    • STEM-META Program
  • News
    • Awards
    • Features
    • Press Releases
  • Contact
✕
  • Home
  • May 2022 FDA awards Phase 1/2a clinical trial to study the effects of Immunis’ platform immunomodulatory product STEM on muscular atrophy in patients with knee osteoarthritis
Immunis Closes $10 Million Financing Round
May 1, 2022

###

Share

Recent News

  • Nov 19, 2024

    Immunis Successfully Completes its Phase 1/2a Clinical Trial Targeting Muscle Atrophy

  • Nov 4, 2024

    Immunis Initiates Non-Terminal Preclinical Studies to Address Canine Muscle Atrophy

  • Sep 10, 2024

    FDA Grants Clearance for Immunis’ Phase II Sarcopenic Obesity Trial

Navigation

  • Home
  • About Us
    • Mission
    • Technology
    • Leadership
  • Overview
    • Pipeline
    • STEM-MYO Program
      • Phase 1/2a Clinical Trial
    • STEM-META Program
  • News
    • Awards
    • Features
    • Press Releases
  • Contact

Contact info

Immunis, Inc.
Irvine, California

contact@immunisbiomedical.com

© 2023 Immunis, Inc. | All Rights Reserved